[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  2.00 2.48% 82.60 81.40 82.60 82.60 80.40 80.40 163,853 16:35:27
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 65.3 15.4 2.5 33.7 383

Ekf Diagnostics Share Discussion Threads

Showing 3726 to 3749 of 3950 messages
Chat Pages: 158  157  156  155  154  153  152  151  150  149  148  147  Older
DateSubjectAuthorDiscuss
26/8/2021
09:22
An item that particularly caught my attention in EKF's Growth Presentation was the launch of Quo-Test A1c Mk II • Built on existing technology platform with enhanced usability and features. Connectivity wireless and LAN • Re-engineered casing to reduce effect of dust and temperature extremes And scheduled for launch in 2022 In the US Quo-Test is FDA cleared, but it is not cleared for screening or diagnosis of diabetes, with the device intended for professional use in a clinical laboratory setting for monitoring long-term glycemic control in individuals previously diagnosed with diabetes. Interestingly, Quo-Test is one of the products being displayed under the title 'Point of Care' at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo next month - hTTps://www.ekfusa.com/events/aacc-2021/ So, with the upgrade to Quo-Test and the increasing incidence of diabetes firmly in mind, I am hopeful that the use and utility of Quo-Test could be expanded in the US, and thus the following provides further food for thought where at the very least, there will be an increase in the need for monitoring HbA1c and replaces the 2015 recommendation that asymptomatic adults ages 40 to 70 who are overweight or obese should be screened - August 24/31, 2021 Screening for Prediabetes and Type 2 Diabetes US Preventive Services Task Force Recommendation Statement Conclusions and Recommendation The USPSTF recommends screening for prediabetes and type 2 diabetes in adults aged 35 to 70 years who have overweight or obesity. Clinicians should offer or refer patients with prediabetes to effective preventive interventions. Abstract Importance An estimated 13% of all US adults (18 years or older) have diabetes, and 34.5% meet criteria for prediabetes. The prevalences of prediabetes and diabetes are higher in older adults. Estimates of the risk of progression from prediabetes to diabetes vary widely, perhaps because of differences in the definition of prediabetes or the heterogeneity of prediabetes. Diabetes is the leading cause of kidney failure and new cases of blindness among adults in the US. It is also associated with increased risks of cardiovascular disease, nonalcoholic fatty liver disease, and nonalcoholic steatohepatitis and was estimated to be the seventh leading cause of death in the US in 2017. Screening asymptomatic adults for prediabetes and type 2 diabetes may allow earlier detection, diagnosis, and treatment, with the ultimate goal of improving health outcomes. Importance According to the Centers for Disease Control and Prevention 2020 National Diabetes Statistics Report, an estimated 13% of all US adults (18 years or older) have diabetes, and 34.5% meet criteria for prediabetes.1 The prevalence of prediabetes and diabetes are higher in older adults. Of persons with diabetes, 21.4% were not aware of or did not report having diabetes, and only 15.3% of persons with prediabetes reported being told by a health professional that they had this condition.1 Estimates of the risk of progression from prediabetes to diabetes vary widely, perhaps because of differences in the definition of prediabetes or the heterogeneity of prediabetes.2 A large cohort study of 77 107 persons with prediabetes reported that the risk of developing diabetes increased with increasing hemoglobin A1c (HbA1c) level and with increasing body mass index (BMI).3 Diabetes is the leading cause of kidney failure and new cases of blindness among adults in the US. It is also associated with increased risks of cardiovascular disease (CVD), nonalcoholic fatty liver disease, and nonalcoholic steatohepatitis4-6 and was estimated to be the seventh leading cause of death in the US in 2017.1 Screening asymptomatic adults for prediabetes and type 2 diabetes may allow earlier detection, diagnosis, and treatment, with the ultimate goal of improving health outcomes. Full update - hTTps://jamanetwork.com/journals/jama/fullarticle/2783414
wan
25/8/2021
16:00
Such a clever move boy post my last Nov top alert. Really impressed with a few intellectual giants on here.
tongosti
25/8/2021
11:38
I doubt many are waiting because we've filtered him months ago.
faz
25/8/2021
11:35
come on then Tong....we're all waiting for your impeccable timing comment.... Say that you bought at 75p before it goes too high
mg1982
24/8/2021
12:08
Phew - started to get worried about you. Thought you had lost your daily enthusiasm. Welcome back:)
tongosti
24/8/2021
11:05
Still here, and as far as I can, still keeping tabs of things that matter (thanks Mirandaj).....and still invested for the long term (no share sales). The following is part of the 2021 – 2024 Growth Strategy 21 hours ago 👀 something big is happening - hTTps://www.linkedin.com/posts/ekf-diagnostics_something-big-is-happening-activity-6835543332890931200--9ve
wan
24/8/2021
10:28
I notice our pal wan has not posted for days... getting a bit tired maybe?
tongosti
24/8/2021
07:52
https://uk.advfn.com/stock-market/london/myhealthchecked-MHC/share-news/MyHealthChecked-PLC-Statement-re-DHSC-press-relea/85898296
mirandaj
16/8/2021
08:47
A reminder From 30th March 2021 presentation Quote: • PBS solution introduced into market Q4 2020 as a low cost alternative to MTM • Manufacturing operations in five locations: Boerne, South Bend, Barleben, Leipzig and Cardiff • Supply contracts with Public Health England, Government of Ireland, universities, private labs and blue-chip industrial partners And Additional production lines for Phosphate Buffered Saline (PBS) established Q1 2021 at Boerne,. South Bend, Barleben and Cardiff sites. End quote 
mirandaj
16/8/2021
08:34
Apologies and correction - In my haste this morning I had not noticed the following - In contrast with the Amazon Test (EUA202760), the Amazon Multi-Target Test is not validated for use with specimens collected in PrimeStore Medium and this medium is not listed as a component of the collection kits for use with this assay. So, the EUA is only based on using PBS, which I believe is centred around collection and logistical issues/constraints. From previous EUA's - Phosphate Buffered Saline (PBS) offers advantages over PrimeStore MTM in terms of supply chain logistics and ease of use due to the absence of potentially hazardous preservative fluid, making it suitable for use as a transport medium for unsupervised home collection of specimens. Food for thought - Depending on the level of testing, including preparedness, one might assume that significantly more PBS will be required than that for the original EUA.
wan
16/8/2021
07:35
I note that Amazon has received two separate and additional Emergency Use Authorizations for PCR-based SARS-CoV-2 tests. 13th August 2021 NEW YORK — The US Food and Drug Administration this week granted separate Emergency Use Authorizations for two PCR-based SARS-CoV-2 tests from Amazon subsidiary STS Lab Holdco The Amazon Multi-Target SARS-CoV-2 Real-Time RT-PCR Test is designed to detect SARS-CoV-2 nucleic acid in anterior nasal swab specimens self-collected on-site at Amazon facilities using the Amazon COVID-19 Collection Kit or Amazon On-Site COVID-19 Test Collection Kit. Samples may also be self-collected at home using the Amazon COVID-19 Test Collection Kit. The test may also be used with pooled samples containing up to five individual self-collected anterior nasal swab specimens. The direct-to-consumer Amazon Multi-Target SARS-CoV-2 Real-Time RT-PCR DTC Test is designed to detect SARS-CoV-2 nucleic acid in individual anterior nasal swab specimens self-collected at home using the Amazon COVID-19 Test Collection Kit DTC or in pooled samples containing up to five individual anterior nasal swab specimens. hTTps://www.360dx.com/molecular-diagnostics/amazon-cleveland-clinic-get-fda-emergency-use-authorizations-sars-cov-2-tests#.YRn4JIhKiF4 I have already checked the FDA EUA's, and both new tests also utilise either PrimeStore MTM or Phosphate Buffered Saline (PBS).
wan
10/8/2021
07:47
Mount Sinai innovation bandwidth set to increase and push boundaries further - Mount Sinai Health System Launches Bold $2 Billion Capital Campaign “Limitless” Campaign has raised $1 billion ahead of schedule for critical clinical centers and research institutes in the wake of the pandemic New York, NY (August 09, 2021) Expanding upon its nearly 170-year history of innovation and discovery, the Mount Sinai Health System has launched a bold capital campaign to raise $2 billion by 2025 that will power the organization into a forward-looking era of advanced patient care, research, and education. With more than $1 billion in gifts raised one year ahead of schedule, this new “Limitless” campaign is the first comprehensive campaign since the formation of the Mount Sinai Health System in 2013, when it merged with the former Continuum Health Partners to become one of the largest health systems in the New York City region. Now, as the public phase of the campaign commences, philanthropy will allow Mount Sinai to realize its goal for the future—to improve human health and equitable care for all through scientific breakthroughs, personalized medicine, and training of the next generation of physician-scientists. “This is a game-changing campaign,” says Kenneth L. Davis, MD, President and Chief Executive Officer of Mount Sinai Health System. “It will support forward-thinking initiatives at Mount Sinai that challenge conventions and push the boundaries of medicine, so we can more rapidly solve today’s most pressing health problems and better the lives of the diverse communities we serve in New York City and around the world.” Through the “Limitless” campaign, Mount Sinai is investing in leading-edge technologies, including artificial intelligence and machine learning that enhance doctors’ ability to predict, diagnose, and treat disease. Intensifying the funding of precision medicine efforts throughout the institution will allow discoveries to move more swiftly from the laboratory to a patient’s bedside. Additional support will accelerate scientific investigations, leading to novel therapeutics for cancer, brain disease, and other devastating conditions, and revolutionary medical developments such as the world’s first human tracheal transplant, which took place at Mount Sinai earlier this year. It will strengthen investments in the Health System’s nationally ranked hospitals, clinical centers, and research spaces to create enhanced facilities that will bolster the work of both emerging and established scientists, as well as elevating the patient experience for everyone who comes to Mount Sinai for care. Full release - hTTps://www.mountsinai.org/about/newsroom/2021/mount-sinai-health-system-launches-bold-two-billion-capital-campaign
wan
09/8/2021
13:41
Interesting price action around 80 chaps. Let's see if this time is for real. Ready to pounce if and when that happens.
tongosti
09/8/2021
07:59
The following, on its own, is not going to set the share price on fire, but as indicated by Bio-techne, it will likely provide for 'another' sustainable long term source of revenue - Bio-Techne Corporation (TECH) Q4 2021 Earnings Call Transcript TECH earnings call for the period ending June 30, 2021. Aug 5, 2021 at 4:01PM COVID was an estimated 3% tailwind to our business in Q4 and approximately 4% tailwind for the year, including revenue from sales of the Kantaro IgG antibody serology kit. Encouragingly, there is growing interest in niche markets forming around our COVID serology assay offering, specifically as a tool to identify immunocompromised individuals that may not have the antibody response following vaccination to neutralize the virus. We expect the COVID research and diagnostics will be around for many years, particularly as new viral strains continue to emerge, making this tailwind a sustainable new layer of our product portfolio going forward. Excerpt available at Fool.com - hTTps://www.fool.com/earnings/call-transcripts/2021/08/05/bio-techne-corporation-tech-q4-2021-earnings-call/
wan
08/8/2021
15:59
A good thing to do with regard to more recruitment: https://www.ekfdiagnostics.com/49-trees-yolk-oats.html
mirandaj
06/8/2021
16:14
Interesting: https://communitynewscorp.com/global-hemoglobin-testing-devices-market-2021-technology-future-trends-business-opportunities-2027/
mirandaj
06/8/2021
16:09
The new norm will be above 80 soon
sirshagalot
06/8/2021
15:56
warming up.
wanttowin
29/7/2021
16:18
9 months on and still under 80. Food for thought maybe? Huge opportunity cost concept comes to mind. Been a raging bull market everywhere else.
tongosti
29/7/2021
08:58
Further food for thought - Recently the US Centers for Disease Control and Prevention, announced that FDA emergency use authorization (EUA) for its 'own' COVID-19 PCR test will be withdrawn at the end of 2021. Some analysts are suggesting that this planned withdrawal could mark a bellwether of Emergency Use Authorisation (EUA) approved COVID-19 tests coming to an end. If this proves to be the case then this could have a large impact on the entire COVID-19 testing industry in the U.S., which is currently comprised almost entirely of COVID-19 tests with only FDA EUA approval, which is similarly applicable to sample collection devices (currently FDA submissions are experiencing longer-than-typical review timelines and delays in initiation of reviews). In contrast to fully FDA approved medical tests, EUAs are only given during a declared emergency; outside of this, an EUA cannot be given and cannot be used, with the same applying to viral transport media. With the pandemic situation at least improving in the US, and economies opening up, the fact that state of emergency cannot last forever is likely to be coming firmly to mind. If the above scenario comes to pass, or for that matter is already being anticipated, then the fact that PrimeStore MTM is a patented, fully FDA cleared sample collection system, should come to the fore in terms of availability post EUA's, not to mention its other enabling and important attributes. However, testing will remain paramount in the monitoring of the prevalence of COVID-19, and thus COVID-19 tests will still be needed, similar to how influenza testing is regularly used. Hence my previous comment implying that PrimeStore MTM is not a flash in the pan product, far from it! And due in part to the pandemic, PrimeStore MTM's has been put firmly onto the map, and its place in terms of diagnostics, sequencing (perhaps overlooked, but very important!) and indeed preparedness, has almost certainly been cemented as a permanent one. I would also add that this applies to many uses outside of Covid-19 detection. I am therefore expecting sample collection products (not just MTM) to become an integral part of EKF's core business, especially as this also dovetails with diagnostic kit production that brings testing closer to the consumer, which as recently indicated, is likely to become a multi-year, irreversible growth opportunity.
wan
28/7/2021
10:39
Food for thought...With Covid now being considered as being with us forever, it's worth keeping mind that as the "influenza season" draws nearer, that PrimeStore MTM can be used to detect and differentiate SARS-CoV-2 from influenza viruses. So, in this regard, I am expecting PrimeStore MTM to potentially be in routine use forever too! PrimeStore MTM has proven effective for high throughput and point of care SARS-CoV-2, Influenza, and multiplex testing (single test to diagnose infection caused by more than one virus). And most recently PrimeStore MTM was validated for the rapid and safe simultaneous detection of SARS-CoV-2 (COVID-19) and influenza A/B viruses on Roche’s cobas Liat®, a point-of-care FDA approved diagnostic system. In short, a sample transport medium that's compatible and safe in differentiating between covid and flu, either separately from the same sample on a range of high-throughput systems, via the same sample for multiplex testing, or simultaneously on point of care platforms.
wan
27/7/2021
07:08
Exceprt from SourceBio's Half Year Trading Update today - As previously reported, the Company anticipates a strong second half bias to revenues, earnings and cash generation, largely driven by the phasing of COVID-19 testing revenues generated through its newest business unit, Infectious Disease Testing. The Group had a solid first half and has completed more than 600,000 PCR-based tests from its laboratory in Nottingham during the period, in addition to tests delivered through mobile units, generating divisional revenues in the half year of approximately GBP28.4 million compared to GBP2.2 million in the first half of 2020. The Group is planning for a significant uplift in demand in the third quarter driven by the anticipated increase in COVID-19 testing as travel restrictions continue to be lifted. The Group has already seen a marked uptick during July with daily testing volumes rising from under 4,000 tests per day in June to approximately 9,000 tests daily at present, well within the Group's existing capacity. Testing demand is expected to rise further and, accordingly, the Group has made preparations to expand its capacity to more than 20,000 tests per day. Should demand exceed these levels, the Group has further arrangements to leverage surplus capacity within a third party owned laboratory. hTTps://uk.advfn.com/stock-market/london/sourcebio-SBI/share-news/SourceBio-International-PLC-Half-Year-Trading-Upda/85671726
wan
24/7/2021
11:28
As predicted, PCR testing volumes has almost certainly increased and perhaps significantly, and (unfortunately) it appears it could stay at relatively high levels going forwards - UK lacks testing capacity to bring pingdemic to a swift end, ministers warned System will not easily be able to meet demand if relaxation of self-isolation rules brought forward, sources say By Ben Riley-Smith, POLITICAL EDITOR; Bill Gardner and Lizzie Roberts 23 July 2021 Even though the daily Covid case count has dipped in recent days, there are concerns in Whitehall that the dropping of almost all major restrictions earlier this week could trigger a new surge. The limits of testing – both PCR and lateral flow tests – are closely linked to the debate about when self-isolation rules can change. One source said that last week ministers ordered more lateral flow tests amid fears they would "run out" by around mid-August. The availability of PCR tests is also coming under pressure. Last week, the NHS admitted that turnaround times for testing in the community had "decreased substantially" since May. Official figures show that the percentage of tests processed within 24 hours fell sharply from 93 per cent in May to 64 per cent in the week ending July 14. A testing source said turnaround times could fall even further if the change to self-isolation rules was brought forward. They warned this could push processing times beyond 72 hours, when samples can go off and produce false negatives. "We are therefore calling on you to ensure that the necessary testing is in place to enable people who have been double vaccinated for longer than two weeks and pinged by the NHS Covid app, to immediately return to work, following a negative PCR test, rather than having to self-isolate.” A Department of Health and Social Care spokesman said: "The testing and tracing being delivered across the country is saving lives every single day and stopping the spread of the virus by breaking chains of transmission and helping to control outbreaks wherever they exist. "NHS Test and Trace has capacity in place to respond to increases in demand and people can have confidence that if they need a test, they can get one. Anyone who has Covid-19 symptoms can book home-testing PCR kits and more booking slots are made available at testing sites each day." Full story - hTTps://www.telegraph.co.uk/news/2021/07/23/uk-lacks-testing-capacity-bring-pingdemic-swift-end-ministers/ And with regard to a particular point raised in the above article that "this could push processing times beyond 72 hours, when samples can go off and produce false negatives." EKF has an answer to that! Cue the attributes of PrimeStore MTM (even if its just in case any extension of the processing times waste the sample and extend the whole testing process further and exacerbating the situation!). It's also why Primestore MTM is effective in enabling downstream sequencing, despite any such delays. Note that EKF has already confirmed that supply contracts have be won with Public Health England, Private Labs and Universities in the UK and has a large contract with distributor to supply the Government of Ireland.
wan
24/7/2021
11:03
In my view, the broad-based strength this large player experienced in the first half provides a good guide/overview of the sector, with the full year outlook also providing a reassuring feature, and at the very least, complimenting the confidence announced by EKF's management in terms of the full year, and indeed the impact from the delivery of their growth strategy - Sciences and Diagnostics Businesses Jul 22, 2021 This story has been updated with information from Danaher's analyst conference call. NEW YORK – Danaher reported before the opening of the market on Thursday that its second quarter revenues rose 37 percent year over year, thanks largely to steep gains from its life sciences and diagnostics businesses. For the three months ended July 2, revenues rose to $7.22 billion from $5.30 billion in the second quarter of 2020, beating the average Wall Street analyst estimate for revenues of $6.72 billion. Revenues for the life sciences business rose 41 percent to $3.73 billion from $2.64 billion, revenues for the diagnostics business also rose 41 percent to $2.34 billion from $1.66 billion, and the company saw a 16 percent increase in the environmental and applied solutions business to $1.15 billion in revenue from $995.0 million in the year-ago quarter. "Broad-based strength across the portfolio helped us deliver over 30 percent core revenue growth and outstanding earnings per share growth and cash flow generation," Danaher President and CEO Rainer Blair said in a statement. "We continued to make significant growth investments during the quarter, strengthening our organic growth trajectory and enhancing our portfolio with the announcement of our pending acquisition of Aldevron." Danaher ended the quarter with $7.32 billion in cash and cash equivalents. For the third quarter, the company said it expects core revenue growth in the mid- to high-teens percent range. Blair said the company expects to deliver approximately 20 percent core revenue growth for full-year 2021. Danaher also expects to recognize $2 billion in COVID-related vaccine and therapeutic revenues in 2021 and anticipates entering 2022 with approximately $1.5 billion in COVID-related backlog revenue. He also noted the company expects to ship approximately 50 million respiratory tests in 2021. Full story - hTTps://www.360dx.com/business-news/danaher-q2-revenues-rise-37-percent-driven-life-sciences-and-diagnostics-businesses#.YPvVHo5KiF4
wan
Chat Pages: 158  157  156  155  154  153  152  151  150  149  148  147  Older
ADVFN Advertorial
Your Recent History
LSE
EKF
Ekf Diagno..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211028 03:29:00